Shire plc: Shire Announces FDA Approval for Label Expansion of CINRYZE for Prevention of Attacks in Pediatric HAE

Shire Announces FDA Approval for Label Expansion of CINRYZE (C1 esterase inhibitor [human]) for Prevention of Attacks in Pediatric Hereditary Angioedema Patients CINRYZE is the first and only ther...

More From BioPortfolio on "Shire plc: Shire Announces FDA Approval for Label Expansion of CINRYZE for Prevention of Attacks in Pediatric HAE"